BioVersys completes its IPO at SIX Swiss Exchange

7 February 2025

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, has completed its Initial Public Offering at the SIX Swiss Exchange at a price of CHF 36.00 per share, implying an offer size and gross proceeds of approximately CHF 80m. Existing shareholders AMR Action Fund, L.P. and AMR Action Fund, SCSp (together the "AMR Action Fund") entered into separate agreements with the Company to purchase shares in an aggregate investment amount equaling gross proceeds of approximately CHF 22m.

VISCHER advises the AMR Action Fund in this transaction with Matthias Staehelin and Timothy Woodtli (both Corporate/M&A).

Author: Matthias Staehelin